Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts and pre-announcements in light of the COVID-19 impact.
The stock that made headlines during the week was Amarin Corporation plc (NASDAQ:AMRN), which slumped on an adverse court ruling.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The following are catalysts that could impact biotech stocks in the unfolding week.
The focus is likely to stay on pre-clinical and clinical updates from companies developing therapies and/or vaccines for SARS-CoV-2. More companies are expected to update investors with preliminary first-quarter results that factor in the COVID-19 impact.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
Conferences
- Goldman Sachs Cell Therapy Day: April 6
- 2020 Wells Fargo Biotech Virtual Corporate Access Day: April 7 in Boston, Massachusetts
- Canaccord Genuity Horizons in Oncology Virtual Event: April 8 in Boston
- 2020 Wells Fargo Biotech Virtual Corporate Access Day: April 9 in San Francisco, California
Clinical Readouts
Menlo Therapeutics Inc (NASDAQ:MNLO): top-line data from two ongoing serlopitant Phase 3 studies in pruritus associated with prurigo nodularis (late March/early April)
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Oragenics Inc (NYSE:OGEN): Results from the Phase 2 study of AG013 in oral mucositis (early 2020)
Earnings
- AngioDynamics, Inc. (NASDAQ:ANGO) (Tuesday after the close)
- PAVmed Inc (NASDAQ:PAVM) (Thursday after the close)
IPOs
Keros Therapeutics, which develops therapies for hematological and neuromuscular disorders, plans to offer 5 million shares in an IPO priced between $14 and $16. The company has applied to list its shares on the Nasdaq under the ticker symbol "KROS."
IPO Quiet Period Expiry
Imara Inc (NASDAQ:IMRA)
Related Links:
Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
10 Biotech Winners And Losers In Q1
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.